Mesothelioma Death Rate Still Rising in Great Britain

Despite banning all forms and uses of asbestos 20 years ago, Great Britain still has one of the world’s highest rates of mesothelioma cancer, according to the government’s Health and Safety Executive report. The July 2019 report revealed the number of annual deaths from mesothelioma in the country still is peaking and expected to begin a gradual decline in 2020. The report included 2,523 deaths in 2017 (the last year available) from mesothelioma, the rare and aggressive cancer caused by exposure to asbestos. It estimates as many as 2,637 others could die in 2019. Great Britain, which comprises the nations of England, Scotland and Wales, averaged 2,560 deaths attributed to mesothelioma from 2012 to 2016. The island banned amosite and crocidolite asbestos — the two most toxic types — in 1985 and completed the ban in 1999 by adding chrysotile asbestos. The report illustrates that it takes several decades after an asbestos ban before seeing a sharply reduced number of mesothelioma deaths. “Countries with bans have had to wait 30 or more years before seeing a reduced incidence rate,” mesothelioma specialist Dr. Raja Flores, a thoracic surgeon at Mount Sinai Hospital in New York, told The Mesothelioma Center at Asbestos.com. “But a ban is better than doing nothing.” Mesothelioma Not Going Away There have been more than 2,000 deaths attributed to mesothelioma in Great Britain each year since 2005. The annual number is not expected t...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

A team of experts from eight different federal agencies has presented the U.S. Food and Drug Administration with preliminary recommendations to standardize the testing of talc for the presence of asbestos and other potentially harmful mineral products. The recommendations, some of which reject long-held talc industry positions, are designed to end the discrepancies in analysis of whether talc products are contaminated with cancer-causing substances. Preliminary recommendations will be part of the FDA’s public meeting on Feb. 4 to discuss and obtain scientific information on testing for asbestos in talc-based products...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conditions:   Thyroid;   Renal Cell Carcinoma;   Non Small Cell Lung Cancer;   Small-cell Lung Cancer;   Bladder Cancer;   Melanoma;   Merkel Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Microsatellite Instability High;   Triple Negative Breast Cancer;   Mesothelioma;   Thym ic Cancer;   Cervical Cancer;   Biliary Tract Cancer;   Hepatocellular Carcinoma;   Ovarian Cancer;   Gastric Cancer;   Head ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Researchers in Spain have discovered a drug combination showing potential in treating the most difficult-to-treat type of malignant mesothelioma. Selumetinib and AZD8186, already being studied separately in clinical trials for other cancers, displayed efficacy when used in combination on mesothelioma of the sarcomatoid cell type. Researchers at the Spanish National Cancer Research Centre made the discovery during their study using mice models and human tumor cells in the laboratory. “The findings, we hope, are relevant,” Dr. Paco Real, who led the study, told The Mesothelioma Center at Asbestos.com. “We d...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
An international research team has identified a novel molecular target with potential to significantly improve future treatment of malignant pleural mesothelioma. The recent findings could lead to a drug that targets key genetic inhibitors often preventing a patient’s own immune system from suppressing mesothelioma tumor growth. Dr. Antonio Giordano, part of the collaborative research team, said the goal is reducing mesothelioma mortality with a combinational therapy that includes this new target. “These findings help us define molecular mechanisms that may be key to mesothelioma aggressiveness and progression,...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Background: Pemetrexed is an antifolate cytostatic drug that targets multiple enzymes involved in folate biosynthesis and is indicated for treatment of non–small-cell lung cancer and malignant pleural mesothelioma. As evidence for an exposure–response/toxicity relationship is accumulating, dose individualization using therapeutic drug monitoring may be a feasible strategy to optimize treatment. The purpose of this study was to develop a simple, sensitive, high-performance liquid chromatography method with UV detection for quantification of pemetrexed levels in human plasma. Method: The method involves a si...
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Short Communication Source Type: research
Publication date: Available online 10 January 2020Source: Pathology - Research and PracticeAuthor(s): Masanori Matsuda, Hironori Ninomiya, Ryo Wakejima, Kentaro Inamura, Sakae Okumura, Mingyon Mun, Masanobu Kitagawa, Yuichi IshikawaAbstractCalretinin, a mesothelioma marker, is sometimes expressed in lung cancer, which may complicate the differential diagnosis of mesothelioma. Here, the clinicopathological and immunohistochemical characteristics of calretinin-positive lung cancer were examined to reduce confusion with malignant mesothelioma. Calretinin expression in 307 consecutive cases of lung cancer was evaluated immunoh...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
In this study, we comprehensively analyzed the expression profile and prognostic value of HOXC11 in human pan-cancer using online The Cancer Genome Atlas (TCGA) databases. HOXC11 was widely up-regulated in tumor tissues when compared with the normal tissues in pan-cancer across nine cancer types. In addition, high mRNA level of HOXC11 predicted poor overall survival (OS) of patients with adrenocortical carcinoma (ACC), colon adenocarcinoma (COAD), kidney renal clear cell carcinoma (KIRC), mesothelioma (MESO) and pancreatic adenocarcinoma (PAAD), respectively. By comparative analysis, we found that HOXC11 was up-regulated a...
Source: Life Sciences - Category: Biology Source Type: research
A patient diagnosed with pleural and peritoneal mesothelioma today can survive well beyond expectations, provided personalized treatment can be found at a specialty center. Research from the Columbia University Medical Center in New York City has shown that despite the poor prognosis typically accompanies this rare diagnosis, patients still can thrive. “This is an understudied, and poorly understood, group of patients that often is just written off,” surgical oncologist Dr. Michael Kluger at Columbia told The Mesothelioma Center at Asbestos.com. “But we’ve shown a meaningful survival.” Kluger,...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusion In our cohort, seafaring was associated with a higher overall incidence of cancer compared to the general population. While the majority of cancers could not be linked to specific occupational facto rs, increases in mesothelioma, lip and non-melanoma-skin cancer indicate previous exposure to asbestos, ultraviolet radiation and potentially also chemicals with dermal carcinogenic properties at sea.byUgelvig Petersen K, Pukkala E, Martinsen JI, Lynge E, Tryggvadottir L, Weiderpass E, Kj ærheim K, Heikkinen S, Hansen J. doi:10.5271/sjweh.3877
Source: Scandinavian Journal of Work, Environment and Health - Category: Occupational Health Tags: Original article Source Type: research
Conclusion In our cohort, seafaring was associated with a higher overall incidence of cancer compared to the general population. While the majority of cancers could not be linked to specific occupational factors, increases in mesothelioma, lip and non-melanoma-skin cancer indicate previous exposure to asbestos, ultraviolet radiation and potentially also chemicals with dermal carcinogenic properties at sea. PMID: 31917456 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Work, Environment and Health - Category: Occupational Health Authors: Tags: Scand J Work Environ Health Source Type: research
More News: Academies | Asbestosis | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Education | Environmental Health | Epidemiology | Government | Health and Safety | Health and Safety Executive | Hospitals | Mesothelioma | Occupational Health | Schools | Scotland Health | Toxicology | UK Health | Universities & Medical Training | Wales Health | Warnings